Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Legal Names
Legal name
Similar Companies1000
Arcellx
Arcellx is a biotech company developing innovative cell therapies for cancer.
Sector
Subsector
Keywords
Location
total rounds
total raised
Harpoon Therapeutics
Harpoon Therapeutics is a clinical-stage immunotherapy company developing T cell engagers to treat cancer and other diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Triumvira Immunologics
Triumvira Immunologics, Inc. is an immunotherapy company that develops T-cell therapies for cancer treatment.
Sector
Subsector
Location
total rounds
total raised
Ziopharm oncology
ZIOPHARM Oncology is a biotechnology company developing gene therapy, cell therapy, and cancer immunotherapy products.
Sector
Subsector
Keywords
Location
total rounds
total raised
Financials
Funding Rounds9
Number of Funding Rounds
Money Raised
Their latest funding was raised on 15.05.2024. Their latest investor Hercules Capital. Their latest round Post-IPO Debt
Hercules Capital
Hercules Capital, Inc. provides senior secured venture growth loans to high-growth, innovative venture capital-backed companies.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
count Of Exists
Genentech
Genentech is a biotechnology company that develops and commercializes innovative medicines to treat serious medical conditions.
Sector
Subsector
Keywords
Location
total rounds
count Of Investments
count Of Exists
Co-Investors
Investors14
Number of lead investors
Number of investors
Hercules Capital
Hercules Capital, Inc. provides senior secured venture growth loans to high-growth, innovative venture capital-backed companies.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
count Of Exists
University of Oxford
Oxford University: large, renowned institution with small, interdisciplinary academic community.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
count Of Exists
QVT Financial
QVT Financial LP is a privately owned hedge fund sponsor.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Acquisitions1
TCR2 acquired by Adaptimmune
acquirer
date
TCR2
TCR2 is a pharmaceutical company that engineers T cells for cancer therapy.
Sector
Subsector
Location
total rounds
total raised
People
Founders2
James Noble
James Noble has served as our full-time Chief Executive Officer since March 2014 and part-time CEO from July 2008 to March 2014 and is one of our co-founders. From July 2008 until March 2014, Mr. Noble was also part-time CEO of Immunocore. Mr. Noble has 24 years of experience in the biotech industry. He has held numerous non-executive director positions, including at CuraGen Corporation, PowderJect Pharmaceuticals plc, Oxford GlycoSciences plc, MediGene AG, and Advanced Medical Solutions plc. Mr. Noble is also Deputy Chairman of GW Pharmaceuticals plc and a non-executive director of Immunocore Limited. Mr. Noble is qualified as a chartered accountant with Pricewaterhouse Coopers and spent seven years at the investment bank Kleinwort Benson Limited, where he became a director in 1990. He then joined British Biotech plc as Chief Financial Officer from 1990 to 1997. Mr. Noble was previously Chief Executive Officer of Avidex Limited, a privately held biotechnology company that was our predecessor, from 2000 to 2006. Mr. Noble holds an MA from the University of Oxford.
current job
organization founded
James Noble
Ian Laing
Ian Laing has served as a Non-Executive Director since December 2008 and is a founder shareholder of the Company. Having started his career in commercial property, Mr. Laing has been an active investor in life science and technology businesses for 25 years. He was previously a founder shareholder and non-executive director of Oxford Asymmetry International Plc (subsequently Evotec) from 1992 to 2000, Doctors.net.uk, Oxagen Limited, Oxford Semiconductor Limited and Phosphonics Limited. He is currently a non-executive director of several private companies including Aegate Limited, SQW Group Limited and Immunocore Limited. Mr. Laing is a Trustee of the Nuffield Medical Trust and was formerly Deputy Chairman of London Business School and a non-executive director of the Oxford Radcliffe Hospitals NHS Trust. He is a Governor of the Royal Shakespeare Company and an Honorary Fellow of Green Templeton College and St. Edmund Hall in the University of Oxford. Mr. Laing holds a BA degree from the University of Oxford and an MBA from London Business School.
current job
organization founded
Ian Laing
Employee Profiles51
Raven Henin
Senior director, im commercial and corporate systems
Helen Mason
Associate director, global infrastructure operations
Paul Newey
Director of it security at adaptimmune limited
Dennis Williams
TitleSr. Vice President, Late Stage Development
Activity
Recent News7
The graph reveals the ratio (%) of positive news articles in a chosen time range